share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

SEC announcement ·  Feb 27 17:10
Summary by Moomoo AI
Ourania Tatsis, EVP, Chief Reg. & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed the sale of company shares on two separate dates. On February 23, 2024, Tatsis sold 3,309 shares of common stock at a price of $431.79 per share. Following this transaction, she disposed of an additional 354 shares on February 26, 2024, at a price of $425.70 per share. The total number of shares sold across both transactions was 3,663, resulting in a combined market value of approximately $1,579,490.91. After these sales, Tatsis directly holds 55,804 shares of Vertex Pharmaceuticals.
Ourania Tatsis, EVP, Chief Reg. & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed the sale of company shares on two separate dates. On February 23, 2024, Tatsis sold 3,309 shares of common stock at a price of $431.79 per share. Following this transaction, she disposed of an additional 354 shares on February 26, 2024, at a price of $425.70 per share. The total number of shares sold across both transactions was 3,663, resulting in a combined market value of approximately $1,579,490.91. After these sales, Tatsis directly holds 55,804 shares of Vertex Pharmaceuticals.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more